MX2015004411A - Compuestos utiles para elaborar inhibidores de proteasa de virus de la hepatitis c (vhc). - Google Patents

Compuestos utiles para elaborar inhibidores de proteasa de virus de la hepatitis c (vhc).

Info

Publication number
MX2015004411A
MX2015004411A MX2015004411A MX2015004411A MX2015004411A MX 2015004411 A MX2015004411 A MX 2015004411A MX 2015004411 A MX2015004411 A MX 2015004411A MX 2015004411 A MX2015004411 A MX 2015004411A MX 2015004411 A MX2015004411 A MX 2015004411A
Authority
MX
Mexico
Prior art keywords
protease inhibitors
hcv protease
compounds useful
making hcv
making
Prior art date
Application number
MX2015004411A
Other languages
English (en)
Inventor
Kenneth M Engstrom
Yanqun Zhao
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2015004411A publication Critical patent/MX2015004411A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Abstract

Se describen compuestos útiles para elaborar inhibidores de proteasa de VHC. También se proveen métodos para utilizar estos compuestos para elaborar inhibidores de proteasa de VHC.
MX2015004411A 2012-10-08 2013-10-07 Compuestos utiles para elaborar inhibidores de proteasa de virus de la hepatitis c (vhc). MX2015004411A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261711001P 2012-10-08 2012-10-08
PCT/US2013/063719 WO2014058794A1 (en) 2012-10-08 2013-10-07 Compounds useful for making hcv protease inhibitors

Publications (1)

Publication Number Publication Date
MX2015004411A true MX2015004411A (es) 2016-04-06

Family

ID=49382650

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004411A MX2015004411A (es) 2012-10-08 2013-10-07 Compuestos utiles para elaborar inhibidores de proteasa de virus de la hepatitis c (vhc).

Country Status (9)

Country Link
US (1) US20140100364A1 (es)
EP (1) EP2903988A1 (es)
JP (1) JP2015533124A (es)
CN (1) CN104822682A (es)
AU (1) AU2013329514A1 (es)
BR (1) BR112015007887A2 (es)
CA (1) CA2887621A1 (es)
MX (1) MX2015004411A (es)
WO (1) WO2014058794A1 (es)

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
UY28240A1 (es) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
CN100363055C (zh) 2003-04-02 2008-01-23 贝林格尔·英格海姆国际有限公司 用作c型肝炎病毒蛋白酶抑制剂的药物组合物
CN1771257A (zh) 2003-04-10 2006-05-10 贝林格尔·英格海姆国际有限公司 通过钌络合物催化的易位反应制备大环化合物的方法
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
PE20050431A1 (es) 2003-09-22 2005-07-19 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005051980A1 (en) 2003-11-20 2005-06-09 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
BRPI0508867A (pt) 2004-03-15 2007-09-04 Boehringer Ingelheim Int processo para a preparação de compostos macrocìclicos
DE102004033312A1 (de) 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
EA200700336A1 (ru) 2004-07-16 2009-12-30 Джилид Сайэнс, Инк. Противовирусные соединения
US7189844B2 (en) 2004-09-17 2007-03-13 Boehringer Ingelheim International Gmbh Ring-closing metathesis process in supercritical fluid
JP2008513454A (ja) 2004-09-17 2008-05-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状ｈｃｖプロテアーゼインヒビターの調製方法
NZ562167A (en) 2005-03-08 2011-01-28 Boehringer Ingelheim Int Process for preparing macrocyclic compounds
US20070237818A1 (en) 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
CN101263156A (zh) * 2005-07-25 2008-09-10 因特蒙公司 C型肝炎病毒复制的新颖大环抑制剂
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
DK1934243T3 (da) 2005-09-09 2011-09-05 Boehringer Ingelheim Int Cykliserende metathesefremgangsmåde til fremstilling af makrocykliske peptider
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20070281884A1 (en) 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
PE20080992A1 (es) 2006-06-26 2008-08-06 Enanta Pharm Inc Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c
CN101674844A (zh) 2006-08-04 2010-03-17 英安塔制药有限公司 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂
US20090035271A1 (en) 2007-08-01 2009-02-05 Ying Sun Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US7582605B2 (en) 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US7605126B2 (en) 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US20120220520A1 (en) 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment
CN101568346B (zh) 2006-10-27 2015-11-25 默沙东公司 Hcv ns3蛋白酶抑制剂
TW200827364A (en) 2006-11-02 2008-07-01 Taigen Biotechnology Co Ltd HCV protease inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008095058A1 (en) 2007-02-01 2008-08-07 Taigen Biotechnology Co. Ltd. Hcv protease inhibitors
MX2009011370A (es) 2007-04-24 2009-11-05 Hoffmann La Roche Proceso para el intermediario del inhibidor proteasa de hcv.
US7906513B2 (en) 2007-04-26 2011-03-15 Enanta Pharmaceuticals, Inc. Hydrazide-containing hepatitis C serine protease inhibitors
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
US20080267917A1 (en) 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US20090005387A1 (en) 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
KR101596524B1 (ko) 2007-06-29 2016-02-22 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
EP2162432A2 (en) 2007-06-29 2010-03-17 Gilead Sciences, Inc. Antiviral compounds
JP5439384B2 (ja) 2007-12-21 2014-03-12 エフ．ホフマン−ラ ロシュ アーゲー 大員環の製造方法
KR20150117305A (ko) 2007-12-21 2015-10-19 셀진 아빌로믹스 리서치, 인코포레이티드 Ｈｃｖ 프로테아제 억제제 및 이의 용도
BRPI0908021A2 (pt) 2008-02-04 2015-07-21 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
JP2011519364A (ja) 2008-04-15 2011-07-07 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
US20090285773A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
JP5529120B2 (ja) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
EP2323981B1 (en) 2008-08-07 2014-03-12 F. Hoffmann-La Roche AG Process for the preparation of a macrocycle
WO2010088394A1 (en) 2009-01-30 2010-08-05 Glaxosmithkline Llc Compounds
EP2417134B1 (en) 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
DK2421527T3 (en) 2009-04-25 2018-08-13 Hoffmann La Roche Methods for improving pharmacokinetics
PL2477980T3 (pl) 2009-09-15 2017-02-28 Taigen Biotechnology Co., Ltd. Inhibitory proteazy hcv
TW201119667A (en) 2009-10-19 2011-06-16 Enanta Pharm Inc Bismacrocyclic compounds as hepatitis C virus inhibitors
EP2504343A4 (en) * 2009-11-24 2013-04-17 Boehringer Ingelheim Int HEPATITIS C INHIBITOR COMPOUNDS
EP2504344A4 (en) * 2009-11-24 2013-06-05 Boehringer Ingelheim Int HEPATITIS C INHIBITOR COMPOUNDS
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US20110178107A1 (en) 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
CA2788155C (en) 2010-01-27 2018-04-24 AB Pharma Ltd. Polyheterocyclic compounds highly potent as hcv inhibitors
US20120095211A1 (en) 2010-09-22 2012-04-19 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication

Also Published As

Publication number Publication date
US20140100364A1 (en) 2014-04-10
AU2013329514A1 (en) 2015-04-30
CN104822682A (zh) 2015-08-05
EP2903988A1 (en) 2015-08-12
JP2015533124A (ja) 2015-11-19
CA2887621A1 (en) 2014-04-17
BR112015007887A2 (pt) 2017-07-04
WO2014058794A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
CO7111289A2 (es) Compuestos inhibidores de metaloenzimas
UY34092A (es) Nuevos compuestos como inhibidores de jak
CR20140463A (es) Compuestos de heterociclilo como inhibidores de mek
IN2014CN02639A (es)
UY34004A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
MX342851B (es) Metodos y materiales para sintesis enzimatica de compuestos mogrosido.
IN2014CN03887A (es)
IN2014DN08481A (es)
IN2014DN06166A (es)
IN2012DE02913A (es)
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
UY33930A (es) Inhibidores novedosos de quinasas
BR112013032555A2 (pt) composição selante híbrida
BR112014027219A2 (pt) método
HK1214252A1 (zh) 作為凝血酶抑制劑的鹵代吡唑
GEP201706626B (en) Synthesis of (s)-nifuratel
IN2014DN09097A (es)
SG11201601150WA (en) Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
IN2013MU01113A (es)
MY168397A (en) Method for Illuminating Space
HK1252173A1 (zh) 用於純化絲氨酸蛋白酶的方法
IN2013MU01290A (es)
WO2014008204A3 (en) Structures of proteasome inhibitors and methods for synthesizing and use thereof
IN2014DN03298A (es)
IL227409A0 (en) Purification of an alpha 1 protease inhibitor obtained from cell culture